Levodopa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), NYE METODER (Norway) and PBAC (Australia), among others, recommended or restricted levodopa, while AWMSG (Wales) did not recommend it.
Assessment has run over 10 years, from 2016 at PBAC (Australia) to 2026 at PBAC (Australia).
No assessment is on file from HAS (France), SMC (Scotland), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 6 of 9 records date from 2023 or later.
3 distinct indication wordings are recorded for levodopa by the agencies that label one in English (AWMSG and PBAC).
4 of these 9 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess levodopa, in 2016; NYE METODER (Norway) did not open a file until 8 Feb 2026 — an unusually long tail of 9.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
PBAC (Australia) is the only agency to have returned to levodopa, recording 4 separate entries.
6 of the 18 agencies in this archive hold a record for levodopa.
The full ledger for levodopa reads 6 recommended, 1 restricted, 1 advice and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 8 Feb 2026 | Til periodisk behandling av episodiske motoriske svingninger (OFF-perioder) hos voksne pasienter med Parkinsons sykdom b… | introduced with conditions | source |
| ZIN (Netherlands) | 19 Dec 2025 | Advies - vergoed levodopa (Inbrija®) voor de behandeling van Parkinson | reimbursed | source |
| TLV (Sweden) | 30 Sep 2025 | Inbrija ingår i högkostnadsskyddet | general subsidy | source |
| PBAC (Australia) | 2024 | Advanced Parkinson disease | Advice Provided | source |
| CIPM (Spain) | 29 Sep 2022 | Indicación terapéutica autorizada: Inbrija está indicado para el tratamiento intermitente de fluctuaciones motoras episó… | financed by the SNS · art. 92 a, c | source |
4 further decisions for levodopa, across 2 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 1 further source document.
Related molecules
- rotigotine — same ATC class N04B — Anti-parkinson
- pramipexole — same ATC class N04B — Anti-parkinson
- rasagiline — same ATC class N04B — Anti-parkinson
- ropinirole — same ATC class N04B — Anti-parkinson
- safinamide — same ATC class N04B — Anti-parkinson
- trametinib — also decided by NYE METODER in 2026Q1
Coverage: 9 decisions for levodopa from 6 agencies, 2016 to 2026. Data to 7 Sep 2026. ATC class N04B — Anti-parkinson. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.